12:00 AM
Jan 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Rindopepimut: Phase II started

Celldex began the double-blind, U.S. Phase II ReACT trial of 500 µg rindopepimut plus granulocyte macrophage colony-stimulating factor (GM-CSF) given 3 times 2 weeks apart followed by a monthly injection in about 95 patients. About 70 Avastin bevacizumab-naïve patients will receive either rindopepimut plus...

Read the full 217 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >